These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 29504736)

  • 1. Anxiolytic effects of venlafaxine/olanzapine combination in treatment of anxious depression.
    Kulhan T; Marcincakova Husarova V; Ondrejka I; Farsky I; Nosalova G
    Neuro Endocrinol Lett; 2018 Feb; 38(8):579-585. PubMed ID: 29504736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comorbid anxiety in late-life depression: Relationship with remission and suicidal ideation on venlafaxine treatment.
    Saade YM; Nicol G; Lenze EJ; Miller JP; Yingling M; Wetherell JL; Reynolds CF; Mulsant BH
    Depress Anxiety; 2019 Dec; 36(12):1125-1134. PubMed ID: 31682328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response.
    Perugi G; Frare F; Toni C; Ruffolo G; Torti C
    Neuropsychobiology; 2002; 46(3):145-9. PubMed ID: 12422062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of venlafaxine alone versus venlafaxine plus bright light therapy combination for severe major depressive disorder.
    Güzel Özdemir P; Boysan M; Smolensky MH; Selvi Y; Aydin A; Yilmaz E
    J Clin Psychiatry; 2015 May; 76(5):e645-54. PubMed ID: 26035199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
    Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes.
    Altmann H; Stahl ST; Gebara MA; Lenze EJ; Mulsant BH; Blumberger DM; Reynolds CF; Karp JF
    J Clin Psychiatry; 2020 Sep; 81(6):. PubMed ID: 32991792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
    Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
    Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression.
    Thase ME; Demyttenaere K; Earley WR; Gustafsson U; Udd M; Eriksson H
    Depress Anxiety; 2012 Jul; 29(7):574-86. PubMed ID: 22753280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study.
    Tsai J; Thase ME; Mao Y; Ng-Mak D; Pikalov A; Loebel A
    CNS Spectr; 2017 Apr; 22(2):236-245. PubMed ID: 28357969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficiency of venlafaxine in patients with psychogenic nonepileptic seizures and anxiety and/or depressive disorders.
    Pintor L; Baillés E; Matrai S; Carreño M; Donaire A; Boget T; Setoain X; Rumia J; Bargalló N
    J Neuropsychiatry Clin Neurosci; 2010; 22(4):401-8. PubMed ID: 21037125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Trazodone Contramid® in clinical practice: personalizing antidepressant intervention].
    Fagiolini A; Amodeo G; Goracci A; Blardi P
    Riv Psichiatr; 2016; 51(4):123-128. PubMed ID: 27727261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impacts of migraine and anxiety disorders on painful physical symptoms among patients with major depressive disorder.
    Hung CI; Liu CY; Chen CY; Yang CH; Wang SJ
    J Headache Pain; 2014 Nov; 15(1):73. PubMed ID: 25382691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine.
    Cassano P; Soares CN; Cohen LS; Lyster AK; Fava M
    Arch Womens Ment Health; 2004 Jul; 7(3):167-71. PubMed ID: 15241662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatigue in female patients with major depression: the effect of comorbid anxiety disorders.
    Ferentinos P; Kontaxakis VP; Havaki-Kontaxaki BJ; Dikeos D; Papadimitriou GN; Lykouras L
    Psychiatriki; 2011; 22(4):320-9. PubMed ID: 22271845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptoms of anxiety in depression: assessment of item performance of the Hamilton Anxiety Rating Scale in patients with depression.
    Vaccarino AL; Evans KR; Sills TL; Kalali AH
    Depress Anxiety; 2008; 25(12):1006-13. PubMed ID: 18800370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.